Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Abbott To Cut Rx Development Costs In Half By Increasing Candidate Attrition

Executive Summary

Abbott believes it can cut the cost of drug development in half by increasing the rate of attrition in the discovery phase, the company said Feb. 9 at a drug development summit sponsored by R&D Directions in Phoenix

You may also be interested in...



AstraZeneca Sets Two NMEs Per Year As Metric Of R&D Success

AstraZeneca is setting a goal of launching two new molecular entities each year, Exec VP-Global Drug Development Martin Nicklasson, PhD, said Feb. 10 at a drug development summit sponsored by R&D Directions in Phoenix

FDA May Ask Congress For Funds To Boost Translational Research For Drugs

FDA is understood to be considering whether legislation could be useful to help promote translational research for pharmaceuticals

Novartis R&D Portfolio Grows 44% Since 2000; Half Of Projects Are NMEs

Novartis' clinical R&D portfolio has grown 44% over the last four years, with new molecular entities representing about half the drugs in development, Global Pharma Development Head Joerg Reinhardt, PhD, said Nov. 19 during Novartis' R&D day in New York

Related Content

UsernamePublicRestriction

Register

PS043324

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel